

Agenda for The new Clinical Trial Regulation explained... break-time sessions to ease your transition!

11 am – 12 pm, Monday 22 November to Thursday 25 November 2021

DATE	ΤΟΡΙϹ	PRESENTER
Monday	Opening remarks	Grainne Power,
22 Nov		Director of Human Products
		Authorisation and
		Registration, HPRA
	General principles and new concepts	
	General principles - CTR vs Directive	Elaine Breslin, Clinical
		Assessment Manager, HPRA
	New concepts – Overview of the authorisation	Shane Gormley, Clinical
	processes, RMS and MSC roles	Assessor, HPRA
	Clinical Trials Information System (CTIS)	Kiara Murphy, Case
		Administrator, HPRA
Tuesday	Post-authorisation, transition and how can	
23 Nov	l prepare?	
	Safety monitoring and reporting	Sandra Bright, Clinical
		Assessor, HPRA
	Post authorisation – substantial modifications	Shane Gormley, Clinical
	and notifications	Assessor, HPRA
	How do I transition my trial to the CTR?	Shane Gormley, Clinical
		Assessor, HPRA
Wednesday	Ireland – how we will implement	
24 Nov		
	National implementing SI - principles	Colm O'Loughlin,
	· <u>-</u> · ·	Department of Health.
	Clinical trials in Ireland – authorisation process	Elaine Breslin, Clinical
		Assessment Manager, HPRA
	NREC-CT: Enabling Ireland's transition to	Aileen Sheehy, Programme
	harmonised assessment under the CTR	Manager, National Office for

Thursday 25 Nov	Compliance aspects	
	Serious breaches	Norah Cassidy, GCP/PV
		Inspector, HPRA
	GCP inspections - changes brought about by	Peter Twomey, GCP-PV
	the CTR	Inspection Manager, HPRA
	IMP manufacture and labelling	Paul Sexton, GMP Policy
		Manager, HPRA and Peter
		Twomey, GCP-PV Inspection
		Manager, HPRA
	Close of event	Grainne Power,
		Director of Human Products
		Authorisation and
		Registration, HPRA